DCM
RETA

Delpha Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Delpha Capital Management’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-3,001
Closed -$85K – 1351
2017
Q4 		$85K Buy
+3,001
New +$83.7K 0.09% 168

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Delpha Capital Management's RETA Position: Q1 2018 in Review

Delpha Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2018, closing a stake of 3,001 shares — an estimated $85K sold.

Delpha Capital Management first reported a position in RETA in Q4 2017 and held it in 1 quarter. The position peaked at $85K in Q4 2017. 86 funds tracked by Wall St. Rank hold RETA as of Q1 2018.

  • Delpha Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 3,001 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2018, an estimated $85K.
  • Delpha Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $85K in Q4 2017.
  • 86 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.